ACBM
ACRO BIOMEDICAL CO., LTD.
Next earnings ≈ Aug 6, 2026 · est. from filing cadence
$0.03
▲ 0.00%$0.03▲ +3614.29%
over 1Y
L $0.00H $0.03
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+0.0%
1M+0.0%
3M+0.0%
YTD+17.1%
1Y—
Hold
Conviction
Horizon
Medium (3–12mo)
High return on equity (26.1%).
Revenue (FY2025) $0.00 · FY2025
ACRO BIOMEDICAL CO., LTD. shows $0.00 in FY2025 revenue, and 26.1% ROE.
Supporting the case: high return on equity (26.1%); conservative balance sheet (liabilities/equity -0.84x).
Is ACBM a buy? The one-page verdict, explained →
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.20M | $659K | $0.00 | $0.00 | $0.00 |
| Gross profit | $260K | $141K | $0.00 | — | — |
| Operating income | -$7.69M | -$15.9M | -$8.80M | -$38.0K | -$154K |
| Net income | -$7.70M | -$15.9M | -$8.81M | -$42.3K | -$101K |
| Diluted EPS | — | -$0.26 | -$0.15 | $0.00 | $0.00 |
| Net margin | -642.8% | -2410.2% | — | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.56M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-6.5%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$4.10K
Altman Z-Score-3319.25 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-05open ↗10-KPeriod ending 2025-12-312026-02-11open ↗8-KPeriod ending 2026-01-042026-01-08open ↗10-QPeriod ending 2025-09-302025-11-10open ↗8-KPeriod ending 2025-08-142025-08-14open ↗10-QPeriod ending 2025-06-302025-08-05open ↗10-QPeriod ending 2025-03-312025-07-24open ↗10-KPeriod ending 2024-12-312025-07-24open ↗10-QPeriod ending 2024-09-302025-07-23open ↗10-QPeriod ending 2024-06-302025-07-23open ↗10-QPeriod ending 2024-03-312025-07-22open ↗10-KPeriod ending 2023-12-312025-07-18open ↗
Frequently asked
- Is ACRO BIOMEDICAL CO., LTD. (ACBM) a buy?
- ACBM currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (26.1%).
- What is ACRO BIOMEDICAL CO., LTD.'s quality score?
- ACBM scores 38.36363636363636/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001622996, latest 10-Q filed 2026-05-05) · EODHD · as of 6/18/2026, 12:42:40 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 18, 2026, 8:42 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.